Advantage Alpha Capital Partners LP Takes Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Advantage Alpha Capital Partners LP acquired a new position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,634 shares of the company’s stock, valued at approximately $334,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the second quarter valued at about $218,000. Rhumbline Advisers purchased a new position in Gyre Therapeutics during the second quarter valued at approximately $123,000. WINTON GROUP Ltd bought a new stake in Gyre Therapeutics during the 2nd quarter worth approximately $220,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Performance

GYRE opened at $12.09 on Wednesday. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $30.40. The company has a fifty day moving average price of $13.67 and a 200-day moving average price of $12.86.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.